This Houston hospital is tapping into tech to best optimize its COVID-19 vaccination process. Photo courtesy of MD Anderson

Across the country, millions of people eagerly await their COVID-19 vaccinations. But many of them are encountering a big roadblock on the path toward eradicating the pandemic: scheduling their shots.

To overcome that hurdle, some organizations have turned to technology. San Antonio-based grocery chain H-E-B, for instance, will let customers schedule COVID-19 vaccinations through a web-based scheduler. As with H-E-B's app, many vaccination-scheduling tools are just now becoming available.

Houston's MD Anderson Cancer Center is one huge step ahead of the vaccination curve, though. Back in September, the hospital — part of the massive Texas Medical Center complex — started planning how it would roll out vaccinations for its more than 21,000-member workforce. As part of that planning, MD Anderson developed an in-house app enabling its employees to schedule their own vaccination appointments.

"We have an incredible team of informatics developers who worked in conjunction with our human resource and employee health leaders to design an app that's accessible on your phone or from any computer," says Dr. Welela Tereffe, chief medical executive at MD Anderson. "The app feeds you information about what appointments are available and then floats an appointment reminder to your calendar as well as sending you text reminders."

Beginning December 15, MD Anderson employees received the hospital's initial round of shots. They were the first employees who used the app to schedule appointments at workplace vaccination clinics. As of January 5, more than 8,700 hospital employees had been vaccinated with the first dose of either the Pfizer vaccine or Moderna vaccine. The immunizations are not mandatory. In all, 10,700 doses of COVID-19 vaccine have been shipped to MD Anderson since December 14, and every one of them is already spoken for.

Yolan Campbell, associate vice president of HR operations at MD Anderson, says the vaccination scheduling app built on knowledge the hospital's team had accumulated throughout 2020 in producing apps for COVID-19 tests and other pandemic-related purposes.

Tereffe notes that COVID-19 vaccination scheduling has "caused a lot of stress" for health care providers. MD Anderson hoped to avoid that stress by incorporating the app into its vaccination plan.

"The app that that our teams have designed is very simple, very user-friendly," Tereffe says. "It prompts you to put in your preferred contact information, both email and phone. It allows you to choose a block of time and a day that you'd like to be vaccinated. And it puts the information right there at your fingertips about the vaccine and the vaccine clinic process so that you can review it in real time."

As soon as an employee chooses an appointment slot, they receive conformation via the app. Through the app, an employee can cancel or reschedule an appointment.

"I think that level of access and control really helps to reassure people that they can trust the process," Tereffe said.

The app also gives MD Anderson more control over the vaccination clinics, according to Campbell and Tereffe. For instance, a dashboard created by IT professionals at the hospital gathers data from the app to track how many vaccinations have been given, how many appointments have been canceled, and which times and days are most popular for vaccinations. Tereffe said those real-time insights have enabled MD Anderson to adjust the operating hours for vaccination clinics.

To supplement the app, MD Anderson provides extra assistance with vaccination scheduling for employees with language or technology barriers, Tereffe said. The hospital also runs a vaccination hotline staffed by HR professionals.

Looking ahead, Tereffe said MD Anderson will accept any COVID-19 vaccine that's been approved by the U.S. Food and Drug Administration (FDA). So far, that's limited to the Pfizer and Moderna versions.

"We have a process in place to hold unique clinics for each type of vaccine and each dose of vaccine to ensure that people get the vaccine that they have chosen … and that they always get the correct second dose," Tereffe said. "Our intent is to help our employees make informed decisions."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

German biotech co. to relocate to Houston thanks to $4.75M CPRIT grant

money moves

Armed with a $4.75 million grant from the Cancer Prevention and Research Institute of Texas, a German biotech company will relocate to Houston to work on developing a cancer medicine that fights solid tumors.

Eisbach Bio is conducting a clinical trial of its EIS-12656 therapy at Houston’s MD Anderson Cancer Center. In September, the company announced its first patient had undergone EIS-12656 treatment. EIS-12656 works by suppressing cancer-related genome reorganization generated by DNA.

The funding from the cancer institute will support the second phase of the EIS-12656 trial, focusing on homologous recombination deficiency (HRD) tumors.

“HRD occurs when a cell loses its ability to repair double-strand DNA breaks, leading to genomic alterations and instability that can contribute to cancerous tumor growth,” says the institute.

HRD is a biomarker found in most advanced stages of ovarian cancer, according to Medical News Today. DNA constantly undergoes damage and repairs. One of the repair routes is the

homologous recombination repair (HRR) system.

Genetic mutations, specifically those in the BCRA1 and BCRA1 genes, cause an estimated 10 percent of cases of ovarian cancer, says Medical News Today.

The Cancer Prevention and Research Institute of Texas (CPRIT) says the Eisbach Bio funding will bolster the company’s “transformative approach to HRD tumor therapy, positioning Texas as a hub for innovative cancer treatments while expanding clinical options for HRD patients.”

The cancer institute also handed out grants to recruit several researchers to Houston:

  • $2 million to recruit Norihiro Goto from the Massachusetts Institute of Technology to MD Anderson.
  • $2 million to recruit Xufeng Chen from New York University to MD Anderson.
  • $2 million to recruit Xiangdong Lv from MD Anderson to the University of Texas Health Science Center at Houston.

In addition, the institute awarded:

  • $9,513,569 to Houston-based Marker Therapeutics for a first-phase study to develop T cell-based immunotherapy for treatment of metastatic pancreatic cancer.
  • $2,499,990 to Lewis Foxhall of MD Anderson for a colorectal cancer screening program.
  • $1,499,997 to Abigail Zamorano of the University of Texas Health Science Center at Houston for a cervical cancer screening program.
  • $1,497,342 to Jennifer Minnix of MD Anderson for a lung cancer screening program in Northeast Texas.
  • $449,929 to Roger Zoorob of the Baylor College of Medicine for early prevention of lung cancer.

On November 20, the Cancer Prevention and Research Institute granted funding of $89 million to an array of people and organizations involved in cancer prevention and research.

West Coast innovation organization unveils new location in Houston suburb to boost Texas tech ecosystem

plugging in

Leading innovation platform Plug and Play announced the opening of its new flagship Houston-area location in Sugar Land, which is its fourth location in Texas.

Plug and Play has accelerated over 2,700 startups globally last year with corporate partners that include Dell Technologies, Daikin, Microsoft, LG Chem, Shell, and Mercedes. The company’s portfolio includes PayPal, Dropbox, LendingClub, and Course Hero, with 8 percent of the portfolio valued at over $100 million.

The deal, which facilitated by the Sugar Land Office of Economic Development and Tourism, will bring a new office for the organization to Sugar Land Town Square with leasing and hiring between December and January. The official launch is slated for the first quarter of 2025, and will feature 15 startups announced on Selection Day.

"By expanding to Sugar Land, we’re creating a space where startups can access resources, build partnerships, and scale rapidly,” VP Growth Strategy at Plug and Play Sherif Saadawi says in a news release. “This location will help fuel Texas' innovation ecosystem, providing entrepreneurs with the tools and networks they need to drive real-world impact and contribute to the state’s technological and economic growth."

Plug and Play plans to hire four full-time equivalent employees and accelerate two startup batches per year. The focus will be on “smart cities,” which include energy, health, transportation, and mobility sectors. One Sugar Land City representative will serve as a board member.

“We are excited to welcome Plug and Play to Sugar Land,” Mayor of Sugar Land Joe Zimmerma adds. “This investment will help us connect with corporate contacts and experts in startups and businesses that would take us many years to reach on our own. It allows us to create a presence, attract investments and jobs to the city, and hopefully become a base of operations for some of these high-growth companies.”

The organization originally entered the Houston market in 2019 and now has locations in Bryan/College Station, Frisco, and Cedar Park in Texas.